- Tytuł:
- Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial
- Autorzy:
- Źródło:
- In The Lancet Infectious Diseases January 2018 18(1):47-57
Czasopismo naukowe